Prophylaxis and treatment of acute graft-versus-host disease

Seminars in Hematology

Volumn 43, Issue 1, 2006, Pages 32-41

  Chao, Nelson J ^a   Chen, Benny J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; CALCINEURIN INHIBITOR; CASPOFUNGIN; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; FOLINIC ACID; GANCICLOVIR; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOTOXIN; METHOTREXATE; METHYLPREDNISOLONE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; RAPAMYCIN; RHODAMINE; RICIN A; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THYMIDINE KINASE; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CLONAL ANERGY; DIARRHEA; DOSE RESPONSE; DRUG INHIBITION; GENETIC TRANSDUCTION; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC CELL; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INNATE IMMUNITY; MEMORY CELL; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEPHROTOXICITY; NONHUMAN; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIGNAL TRANSDUCTION; SUICIDE GENE; SURVIVAL RATE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TREATMENT FAILURE;

EID: 30344440733     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.09.007     Document Type: Article

References (106)

1. G.B. Vogelsang, L. Lee, D.M. Bensen-Kennedy Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant Annu Rev Med 54 2003 29 52
2. G. Socie, J.V. Stone, J.R. Wingard Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry N Engl J Med 341 1999 14 21
3. J.H. Antin, J.L. Ferrara Cytokine dysregulation and acute graft-versus-host disease Blood 80 1992 2964 2968
4. M.M. Horowitz, R.P. Gale, P.M. Sondel Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 1990 555 562
5. H.J. Kolb, J. Mittermuller, C. Clemm Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients Blood 76 1990 2462 2465
6. D.W. van Bekkum, J. Roodenburg, P.J. Heidt, W.D. van der Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora J Natl Cancer Inst 52 1974 401 404
7. R. Storb, R.L. Prentice, C.D. Buckner Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment N Engl J Med 308 1983 302 307
8. J.L. Ferrara, R. Levy, N.J. Chao Pathophysiologic mechanisms of acute graft-vs.-host disease Biol Blood Marrow Transplant 5 1999 347 356
9. R.A. Clift, C.D. Buckner, F.R. Appelbaum Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission A randomized trial of two irradiation regimens Blood 76 1990 1867 1871
10. G.R. Hill, T. Teshima, A. Gerbitz Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia J Clin Invest 104 1999 459 467
11. B.D. Johnson, R.L. Truitt Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease Blood 85 1995 3302 3312
12. A.J. Barrett, D. Mavroudis, J. Tisdale T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect Bone Marrow Transplant 21 1998 543 551
13. E. Holler, H.J. Kolb, A. Moller Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation Blood 75 1990 1011 1016
14. M.R. Shalaby, B. Fendly, K.C. Sheehan, R.D. Schreiber, A.J. Ammann Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha Transplantation 47 1989 1057 1061
15. P.F. Piguet, G.E. Grau, B. Allet, P. Vassalli Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease J Exp Med 166 1987 1280 1289
16. A. Panoskaltsis-Mortari, D.L. Lacey, D.A. Vallera, B.R. Blazar Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice Blood 92 1998 3960 3967
17. O.I. Krijanovski, G.R. Hill, K.R. Cooke Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease Blood 94 1999 825 831
18. A. Bacigalupo, T. Lamparelli, P. Bruzzi Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) Blood 98 2001 2942 2947
19. M. Remberger, B. Storer, O. Ringden, C. Anasetti Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors Bone Marrow Transplant 29 2002 391 397
20. N. Basara, H. Baurmann, K. Kolbe Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia Results from the multicenter German cooperative study group Bone Marrow Transplant 35 2005 1011 1018
21. J.M. den Haan, N.E. Sherman, E. Blokland Identification of a graft versus host disease-associated human minor histocompatibility antigen Science 268 1995 1476 1480
22. E. Goulmy, R. Schipper, J. Pool Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation N Engl J Med 334 1996 281 285
23. A. Sette, J. Alexander, H.M. Grey Interaction of antigenic peptides with MHC and TCR molecules Clin Immunol Immunopathol 76 1995 S168 S171
24. Y. Yang, J.M. Wilson CD40 ligand-dependent T cell activation Requirement of B7-CD28 signaling through CD40 Science 273 1996 1862 1864
25. J.M. Green, P.J. Noel, A.I. Sperling Absence of B7-dependent responses in CD28-deficient mice Immunity 1 1994 501 508
26. G.J. Freeman, J.G. Gribben, V.A. Boussiotis Cloning of B7-2 A CTLA-4 counter-receptor that costimulates human T cell proliferation Science 262 1993 909 911
27. E.C. Guinan, V.A. Boussiotis, D. Neuberg Transplantation of anergic histoincompatible bone marrow allografts N Engl J Med 340 1999 1704 1714
28. C. Vezina, A. Kudelski, S.N. Sehgal Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle J Antibiot (Tokyo) 28 1975 721 726
29. W.G. Morice, G.J. Brunn, G. Wiederrecht, J.J. Siekierka, R.T. Abraham Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes J Biol Chem 268 1993 3734 3738
30. J. Nourse, E. Firpo, W.M. Flanagan Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin Nature 372 1994 570 573
31. A. Altmeyer, F.J. Dumont Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma Cytokine 5 1993 133 143
32. J.H. Lai, T.H. Tan CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin J Biol Chem 269 1994 30077 30080
33. + regulatory T cells Blood 2005
34. R. Storb, R.B. Epstein, T.C. Graham, E.D. Thomas Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts Transplantation 9 1970 240 246
35. R. Storb, H.J. Deeg, J. Whitehead Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia N Engl J Med 314 1986 729 735
36. O. Ringden, S. Klaesson, B. Sundberg Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings Bone Marrow Transplant 9 1992 19 25
37. T.J. Nevill, M.H. Tirgan, H.J. Deeg Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation Bone Marrow Transplant 9 1992 349 354
38. V. Ratanatharathorn, R.A. Nash, D. Przepiorka Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 92 1998 2303 2314
39. R.A. Nash, J.H. Antin, C. Karanes Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors Blood 96 2000 2062 2068
40. M. Suthanthiran, R.E. Morris, T.B. Strom Immunosuppressants Cellular and molecular mechanisms of action Am J Kidney Dis 28 1996 159 172
41. T. Hovi, A.C. Allison, J. Allsop Rapid increase of phosphoribosyl pyrophosphate concentration after mitogenic stimulation of lymphocytes FEBS Lett 55 1975 291 293
42. R. Storb, C. Yu, J.L. Wagner Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 89 1997 3048 3054
43. J.L. Ferrara, H.J. Deeg Graft-versus-host disease N Engl J Med 324 1991 667 674
44. P.A. Henkart, M.V. Sitkovsky Cytotoxic lymphocytes. Two ways to kill target cells Curr Biol 4 1994 923 925
45. D.W. Mason Subsets of T cells in the rat mediating lethal graft versus-host disease Transplantation 32 1981 222 226
46. + T cell clones secrete the Th1 pattern of cytokines J Immunol 144 1990 1744 1752
47. + T cells J Exp Med 184 1996 19 29
48. W.I. Bensinger, P.J. Martin, B. Storer Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers N Engl J Med 344 2001 175 181
49. M. Mielcarek, L. Graf, G. Johnson, B. Torok-Storb Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products a mechanism for monocyte-mediated suppression of T-cell proliferation Blood 92 1998 215 222
50. R. Powles, J. Mehta, S. Kulkarni Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases A randomised trial Lancet 355 2000 1231 1237
51. Y.G. Yang, B.R. Dey, J.J. Sergio, D.A. Pearson, M. Sykes Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12 J Clin Invest 102 1998 2126 2135
52. + suppressor T cells Immunol Rev 182 2001 58 67
53. P.A. Taylor, C.J. Lees, B.R. Blazar The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality Blood 99 2002 3493 3499
54. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation Nat Med 9 2003 1144 1150
55. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative Eur J Immunol 34 2004 336 344
56. B. Korngold, J. Sprent Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow J Exp Med 148 1978 1687 1698
57. V.T. Ho, R.J. Soiffer The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation Blood 98 2001 3192 3204
58. R.L. Truitt, B.D. Johnson Principles of graft-vs.-leukemia reactivity Biol Blood Marrow Transplant 1 1995 61 68
59. + T cells by virtue of their receptor beta loci sequences Proc Natl Acad Sci U S A 100 2003 1180 1184
60. J.G. Gribben, E.C. Guinan, V.A. Boussiotis Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy A method to ameliorate graft- versus-host disease and extend the donor pool Blood 87 1996 4887 4893
61. B.R. Blazar, P.A. Taylor, R.J. Noelle, D.A. Vallera CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses J Clin Invest 102 1998 473 482
62. + T cell alloantigen-specific hyporesponsiveness by IL- 10 and TGF-beta J Immunol 163 1999 3684 3691
63. M. Cavazzana-Calvo, C. Fromont, F. Le Deist Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin Transplantation 50 1990 1 7
64. S.R. Solomon, T. Tran, C.S. Carter Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes A strategy for GvHD prophylaxis in allogeneic PBSC transplantation Cytotherapy 4 2002 395 406
65. B.J. Chen, X. Cui, C. Liu, N.J. Chao Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process Blood 99 2002 3083 3088
66. M. Guimond, A. Balassy, M. Barrette P-glycoprotein targeting a unique strategy to selectively eliminate immunoreactive T cells Blood 100 2002 375 382
67. I. Andre-Schmutz, F. Le Deist, S. Hacein-Bey-Abina Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation A phase 1/2 study Lancet 360 2002 130 137
68. + cells from stem cell allografts can reduce acute graft-versus-host disease following matched related donor transplantation Blood 104 2004 125A
69. B.J. Chen, X.Y. Cui, G.D. Sempowski, C.X. Liu, N.J. Chao Transfer of aflogeneic CD62L(-) memory T cells without graft-versus-host disease Blood 103 2004 1534 1541
70. + T cells do not induce graft-versus-host disease J Clin Invest 112 2003 101 108
71. + T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity Blood 103 2004 3970 3978
72. E. Xystrakis, I. Bernard, A.S. Dejean Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset Eur J Immunol 34 2004 408 417
73. C. Bonini, G. Ferrari, S. Verzeletti HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia Science 276 1997 1719 1724
74. P. Fontaine, G. Roy-Proulx, L. Knafo Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease Nat Med 7 2001 789 794
75. L. Ruggeri, M. Capanni, M.F. Martelli, A. Velardi Cellular therapy Exploiting NK cell alloreactivity in transplantation Curr Opin Hematol 8 2001 355 359
76. L. Ruggeri, M. Capanni, E. Urbani Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097 2100
77. A. Bendelac, O. Lantz, M.E. Quimby CD1 recognition by mouse NK1+ T lymphocytes Science 268 1995 863 865
78. S.A. Porcelli The CD1 family A third lineage of antigen-presenting molecules Adv Immunol 59 1995 1 98
79. D. Zeng, D. Lewis, S. Dejbakhsh-Jones Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease J Exp Med 189 1999 1073 1081
80. T. Furlong, R. Storb, C. Anasetti Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities Bone Marrow Transplant 26 2000 985 991
81. E. Thomas, R. Storb, R.A. Clift Bone-marrow transplantation (first of two parts) N Engl J Med 292 1975 832 843
82. E. Holler, H.J. Kolb, W. Wilmanns Treatment of GVHD - TNF-antibodies and related antagonists Bone Marrow Transplant 12 suppl 3 1993 S29 S31
83. T. Ruutu, J. Hermans, A. van Biezen European Group for Blood and Marrow Transplantation How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party Bone Marrow Transplant 22 1998 614 615
84. M.T. Van Lint, C. Uderzo, A. Locasciulli Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation Blood 92 1998 2288 2293
85. P.J. Martin, G. Schoch, L. Fisher A retrospective analysis of therapy for acute graft-versus-host disease Initial treatment Blood 76 1990 1464 1472
86. D. Weisdorf, R. Haake, B. Blazar Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation An analysis of clinical risk features and outcome Blood 75 1990 1024 1030
87. I.M. Hings, A.H. Filipovich, W.J. Miller Prednisone therapy for acute graft-versus-host disease Short- versus long-term treatment. A prospective randomized trial Transplantation 56 1993 577 580
88. P.J. Martin, B.J. Nelson, F.R. Appelbaum Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation Blood 88 1996 824 830
89. J.Y. Cahn, P. Bordigoni, P. Tiberghien Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study Transplantation 60 1995 939 942
90. L. Cragg, B.R. Blazar, T. Defor A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease Biol Blood Marrow Transplant 6 2000 441 447
91. A. Bacigalupo, R. Oneto, T. Lamparelli Pre-emptive therapy of acute graft-versus-host disease A pilot study with antithymocyte globulin (ATG) Bone Marrow Transplant 28 2001 1093 1096
92. K. Hattori, T. Hirano, H. Miyajima Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies Blood 91 1998 4051 4055
93. E. Stuber, A. Buschenfeld, A. Von Freier, T. Arendt, U.R. Folsch Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction Effect of pentoxifylline on the development of mucosal atrophy Gut 45 1999 229 235
94. M. Daneshpouy, G. Socie, M. Lemann Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease Blood 99 2002 3033 3040
95. N. Basara, M.G. Kiehl, W. Blau Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients Four years of experience Transplant Proc 33 2001 2121 2123
96. K.C. Doney, P.L. Weiden, R. Storb, E.D. Thomas Treatment of graft-versus-host disease in human allogeneic marrow graft recipients A randomized trial comparing antithymocyte globulin and corticosteroids Am J Hematol 11 1981 1 8
97. C. Anasetti, P.J. Martin, R. Storb Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody Transplantation 54 1992 844 851
98. P.A. Carpenter, F.R. Appelbaum, L. Corey A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease Blood 99 2002 2712 2719
99. S.J. Lee, D. Zahrieh, E. Agura Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease Results of a randomized trial Blood 104 2004 1559 1564
100. H.J. Deeg, B.R. Blazar, B.J. Bolwell Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL Blood 98 2001 2052 2058
101. P. Ely, J. Dunitz, J. Rogosheske, D. Weisdorf Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease Am J Med 90 1991 707 710
102. B. Grothaus-Pinke, S. Gunzelmann, A.A. Fauser, M.G. Kiehl Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel Report of an initial experience Transplantation 72 2001 1456 1458
103. H. Bertz, M. Afting, W. Kreisel Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD Bone Marrow Transplant 24 1999 1185 1189
104. G.B. McDonald, M. Bouvier, D.M. Hockenbery Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease Arandomized, controlled trial Gastroenterology 115 1998 28 35
105. L.E. French, J. Tschopp Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease Potential for therapeutic inhibition Schweiz Med Wochenschr 130 2000 1656 1661
106. B.C. Biedermann, S. Sahner, M. Gregor Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease Lancet 359 2002 2078 2083